NR5A1
Steroidogenic factor 1
Also known as: AD4BP, ELP, FTZ1, FTZF1, hSF-1, SF-1, SF1, STF1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13285
- Gene
- NR5A1
- Ensembl
- ENSG00000136931
- Chromosome
- 9
- Canonical length
- 461 aa
- Protein class
- Disease related genes, Human disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
The protein encoded by this gene is a transcriptional activator involved in sex determination. The encoded protein binds DNA as a monomer. Defects in this gene are a cause of XY sex reversal with or without adrenal failure as well as adrenocortical insufficiency without ovarian defect. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
461 residues, UniProt reviewed canonical sequence.
>Q13285|NR5A1
1 MDYSYDEDLD ELCPVCGDKV SGYHYGLLTC ESCKGFFKRT VQNNKHYTCT ESQSCKIDKT
61 QRKRCPFCRF QKCLTVGMRL EAVRADRMRG GRNKFGPMYK RDRALKQQKK AQIRANGFKL
121 ETGPPMGVPP PPPPAPDYVL PPSLHGPEPK GLAAGPPAGP LGDFGAPALP MAVPGAHGPL
181 AGYLYPAFPG RAIKSEYPEP YASPPQPGLP YGYPEPFSGG PNVPELILQL LQLEPDEDQV
241 RARILGCLQE PTKSRPDQPA AFGLLCRMAD QTFISIVDWA RRCMVFKELE VADQMTLLQN
301 CWSELLVFDH IYRQVQHGKE GSILLVTGQE VELTTVATQA GSLLHSLVLR AQELVLQLLA
361 LQLDRQEFVC LKFIILFSLD LKFLNNHILV KDAQEKANAA LLDYTLCHYP HCGDKFQQLL
421 LCLVEVRALS MQAKEYLYHK HLGNEMPRNN LLIEMLQAKQ TLocalizationUniProt · AlphaFold · HPA
Whether an antibody against NR5A1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 182 nTPM
Expression across tissuesHPA
Tissue
- adrenal gland: 182 nTPM
- spleen: 137 nTPM
- ovary: 36 nTPM
- pituitary gland: 20 nTPM
- testis: 14 nTPM
- hypothalamus: 1.1 nTPM
Single-cell type
- gonadotrophs: 100 nCPM
- adrenal cortex cells: 90 nCPM
- leydig cells: 25 nCPM
- granulosa cells: 24 nCPM
- ovarian stromal cells: 19 nCPM
- sertoli cells: 17 nCPM
Immune cell
- plasmacytoid DC: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
Brain region
- hypothalamus: 38 nTPM
- pons: 0.7 nTPM
- hippocampal formation: 0.4 nTPM
- amygdala: 0.3 nTPM
- cerebellum: 0.3 nTPM
- cerebral cortex: 0.3 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about NR5A1.
Disease | AllUniProt
Conditions NR5A1 is implicated in, by any mechanism.
- 46,XY sex reversal 3 (SRXY3) MIM:612965
- 46,XX sex reversal 4 (SRXX4) MIM:617480
- Adrenal insufficiency, NR5A1-related (AINR) MIM:612964
- Premature ovarian failure 7 (POF7) MIM:612964
- Spermatogenic failure 8 (SPGF8) MIM:613957
Disease | GeneticClinVar
132 pathogenic / likely-pathogenic of 362 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- 46,XY sex reversal 3
- Oligosynaptic infertility
- 46 XY differences of sex development
- Premature ovarian failure 7
- NR5A1-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.26
- gnomAD pLI
- 0.99
- gnomAD missense Z
- 2.34
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adrenal gland development
- calcineurin-mediated signaling
- female gonad development
- hormone metabolic process
- hormone-mediated signaling pathway
- Leydig cell differentiation
- luteinization
- maintenance of protein location in nucleus
- male gonad development
- male sex determination
- negative regulation of female gonad development
- positive regulation of gene expression
- positive regulation of male gonad development
- positive regulation of transcription by RNA polymerase II
- regulation of steroid biosynthetic process
- regulation of transcription by RNA polymerase II
- response to gonadotropin-releasing hormone
- Sertoli cell differentiation
- sex determination
- tissue development
- transcription by RNA polymerase II
- primary sex determination
Molecular functions
- chromatin binding
- DNA binding
- DNA-binding transcription factor activity, RNA polymerase II-specific
- enzyme binding
- nuclear receptor activity
- phospholipid binding
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
- transcription coregulator binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Nuclear hormone receptor, ligand-binding domain
- Zinc finger, nuclear hormone receptor-type
- Nuclear hormone receptor
- Zinc finger, NHR/GATA-type
- Nuclear hormone receptor family 5-like
- Nuclear hormone receptor-like domain superfamily
- Ligand-binding domain of nuclear hormone receptor
- Double treble clef zinc finger, C4 type
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of NR5A1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NR5A1 as an antibody target. Whether an autoantibody or antibody against NR5A1 could matter depends on whether native NR5A1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NR5A1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NR5A1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...